Keryx Biopharmaceuticals Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 12 of 12 Posts
Back On Track
Article By: Warren Bevan Tuesday, September 27, 2016 10:26 PM EDT
Stocks staged a nice comeback after the first presidential debate Monday evening. I continue to see stocks acting great, as they should, in a bull market.
In this article: REN, AMZN, KERX, SPY, BABA, MOMO, ACIA, LITE, TWLO
Read
Invest Like Seth Klarman: Paypal Holdings Inc., Keryx Biopharmaceuticals, Micron Technology, Inc.
Article By: TipRanks Tuesday, January 19, 2016 11:03 AM EDT
In the 3Q, Klarman’s hedge fund, Baupost Group, had a rough quarter, losing 22.42% of its value compared to the S&P 500 which lost about 7% in the same time period.
In this article: MU, KERX, PYPL
Read
Thursday Morning’s Pre-Market Insights: KERX, SNDK, QCOM, And CRUS
Article By: TipRanks Thursday, July 23, 2015 8:29 AM EDT
Cirrus Logic, Inc. shares spiked more than 20% in pre-market trading to $33.85m after beating estimates on solid first quarter earnings. The company posted first quarter revenue of $282.6m, surpassing the consensus estimate of $260.73m.
In this article: CRUS, QCOM, SNDK, KERX
Read
Brean Capital Weighs In On Keryx Biopharmaceuticals Inc. And Rockwell Medical Inc. In Light Of Dialysis Drugs
Article By: TipRanks Tuesday, June 23, 2015 12:47 PM EDT
On June 22, Brean Capital analyst Jonathan Aschoff weighed in on Keryx Biopharmaceuticals Inc. and Rockwell Medical Inc. to provide commentary on both companies’ dialysis drugs.
In this article: KERX, RMTI
Read
Analysts Positive On Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data
Article By: TipRanks Tuesday, May 5, 2015 11:24 AM EDT
Keryx posted total revenue of $1.175 million, including 1,218 prescriptions filled for Auryxia in the quarter.
In this article: KERX
Read
Heavy Insider Buying Could Signal Big Rallies For These 3 Stocks
Article By: Bret Jensen Tuesday, April 14, 2015 9:52 PM EDT
Here are a few small biotech stocks that have garnered considerable interest recently from notable investors as of late.
In this article: KERX, CGIX, SNTA
Read
Keryx's Q4 Loss Misses Expectation, Auryxia In Focus - February 27, 2015
Article By: Zacks Investment Research Friday, February 27, 2015 9:21 AM EDT
Keryx Biopharmaceuticals Inc. is a New York-based biopharmaceutical company working in the field of renal diseases. The company entered this field with the launch of its first product, Auryxia in Dec 2014
In this article: KERX
Read
Insider Trading Report Edition #237: Notable Buys And Sales
Article By: Asif Suria Sunday, January 4, 2015 8:16 AM EDT
Insider buying declined last week with insiders buying $18.4 million of stock compared to $83.07 million in the week prior. Selling also declined sharply with insiders selling $258.37 million of stock.
In this article: BH, OCIP, SLCA, OAS, CFNL, GHC, JAZZ, KERX, AMP, SCTY
Read
APRI Announces First Patient Enrolled In Phase 2a Trial For RayVa; Keryx Announces Issuance Of New U.S. Patent For Auryxia
Article By: BioMedReports Thursday, December 4, 2014 8:25 PM EDT
A look at some of the headlines for companies that made news in the healthcare sector on December 4, 2014, including APRI, KERX, ALDX, CCXI
In this article: APRI, KERX, CCXI, ALDX
Read
PRTA Reports Initiation Of NEOD001 Global Phase 3; KERX Offers Phase 2 Trial Results For Auryxia
Article By: BioMedReports Wednesday, December 3, 2014 3:20 AM EDT
PRTA announced the initiation of the VITAL Amyloidosis Study. KERX announced the publication of Auryxia phase 2 clinical trial results.
In this article: KERX, PRTA
Read
What Investors Should Know About Keryx Pharmaceuticals
Article By: Retail Investor 360 Sunday, September 14, 2014 3:42 PM EDT
Since the FDA approved Ferric Citrate, KERX's share price went up 28%. Wall Street analysts, however, are concerned about the drug's warning label of iron overload. But do doctors share that same concern?
In this article: KERX
Read
E Small Cap Report
Article By: E.B. Capital Markets Thursday, March 20, 2014 1:39 PM EDT
The highest scoring names in small cap from 1 year ago (3/20/2013) returned 3,708 bps more than the S&P 500. The best performers have been RAD up 255%, CAMP up 205%, JAZZ up 163%, MDSO up 127%, GBX up 109%, and HOMB up 90%.
In this article: CDI, CGX, CHE, CMO, CWT, EXAM, FSS, GBX, GTS, PGI, RAD, STRI, WWE, AFFY, ALIM, ANAC, BABY, CYBX, DXPE, DXYN, ECOL, FLDM, GERN, HOMB, HTWR, IRWD, IVAC, JAZZ, MDSO, MPWR, NLNK, PENX, PHMD, REDF, RTIX, SABA, SGMO, SILC, SNTA, VASC, AGYS, AMED, ANIK, BJRI, BLDR, CAMP, CENX, CFNL, DIOD, ELNK, FINL, FORM, GLRE, LCAV, SNHY, STFC, TQNT, UEIC, UNTD, WIRE, XRTX, EBIX, KERX
Read
1 to 12 of 12 Posts